Neflamapimod is under clinical development by CervoMed and currently in Phase II for Alzheimer’s Disease. According to GlobalData, Phase II drugs for Alzheimer’s Disease have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Neflamapimod’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Neflamapimod (VX-745) is under development for the treatment of Alzheimer’s disease, Lewy body dementia, cognitive defects in Huntington disease, acute ischemic stroke and Down syndrome. The drug candidate is administered through oral route as a hard gelatin capsule. It acts by targeting alpha isoform of the protein enzyme p38 mitogen-activated protein kinase (p38 MAPK alpha). It was also under development for the treatment of rheumatoid arthritis.
CervoMed, formerly Diffusion Pharmaceuticals Inc, is a clinical-stage biotechnology company. It develops standard-of-care therapies. The company improves cancer treatments such as radiation therapy and chemotherapy in treatment-resistant solid tumors, including multiple FDA orphan-designated indications. It offers new and small-molecule drugs for regulating the movement of oxygen into tissue and treatment for stroke, treatment-resistant cancerous tumors, glioblastoma multiforme, pancreatic cancer, and brain metastases. CervoMed develops trans sodium crocetinate, a synthetic small molecule that improves the diffusion of oxygen into hypoxic tissue and sensitizes the tumor to radiation therapy. The company offers products for cancer, stroke and heart attack. It performs clinical studies on pancreatic cancer and brain metastasis through cancer centers. CervoMed is headquartered in Charlottesville, Virginia, the US.
For a complete picture of Neflamapimod’s drug-specific PTSR and LoA scores, buy the report here.